Global Recombinant Influenza Vaccine Market Insights, Forecast to 2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Recombinant Influenza Vaccine Market Insights, Forecast to 2034
Recombinant technology plays an important role in the preparation of influenza vaccines. It allows scientists to create and express specific influenza virus proteins through genetic engineering to prepare influenza vaccines. This approach typically involves inserting the genetic sequence of the influenza virus into an expression system, enabling it to produce viral antigen proteins, and then using these proteins to prepare a vaccine.
Global Recombinant Influenza Vaccine market is expected to reach to US$ 115.5 million in 2024, with a positive growth of %, compared with US$ 106.8 million in 2022. Backed with the increasing demand from downstream industries, Recombinant Influenza Vaccine industry is evaluated to reach US$ 188.4 million in 2029. The CAGR will be 8.5% during 2024 to 2029.
A significant driver in the Influenza Vaccine market is the growing awareness of the importance of vaccination in preventing seasonal and pandemic influenza outbreaks. As healthcare organizations and governments worldwide promote vaccination as a crucial public health measure, there is an increasing demand for influenza vaccines. Additionally, advances in vaccine research and development, including the production of more effective and broader-spectrum vaccines, are driving market growth. One of the key challenges in this market is the need for frequent vaccine updates to match evolving influenza strains. The virus undergoes genetic changes, requiring annual adjustments to vaccine formulations. This presents logistical challenges for manufacturers in terms of timely production and distribution. Vaccine hesitancy and misinformation also pose challenges by impacting vaccination rates and public perception. Lastly, ensuring equitable access to vaccines, especially in low-income and underserved populations, remains a persistent challenge in the fight against influenza.
Report Covers
This report presents an overview of global Recombinant Influenza Vaccine market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Recombinant Influenza Vaccine market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report
Sanofi
Segment by Type
Vial
Prefilled
Public Sector
Private Sector
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Recombinant Influenza Vaccine plant distribution, commercial date of Recombinant Influenza Vaccine, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Recombinant Influenza Vaccine introduction, etc. Recombinant Influenza Vaccine Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports’s Conclusions of Recombinant Influenza Vaccine
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports
Global Recombinant Influenza Vaccine market is expected to reach to US$ 115.5 million in 2024, with a positive growth of %, compared with US$ 106.8 million in 2022. Backed with the increasing demand from downstream industries, Recombinant Influenza Vaccine industry is evaluated to reach US$ 188.4 million in 2029. The CAGR will be 8.5% during 2024 to 2029.
A significant driver in the Influenza Vaccine market is the growing awareness of the importance of vaccination in preventing seasonal and pandemic influenza outbreaks. As healthcare organizations and governments worldwide promote vaccination as a crucial public health measure, there is an increasing demand for influenza vaccines. Additionally, advances in vaccine research and development, including the production of more effective and broader-spectrum vaccines, are driving market growth. One of the key challenges in this market is the need for frequent vaccine updates to match evolving influenza strains. The virus undergoes genetic changes, requiring annual adjustments to vaccine formulations. This presents logistical challenges for manufacturers in terms of timely production and distribution. Vaccine hesitancy and misinformation also pose challenges by impacting vaccination rates and public perception. Lastly, ensuring equitable access to vaccines, especially in low-income and underserved populations, remains a persistent challenge in the fight against influenza.
Report Covers
This report presents an overview of global Recombinant Influenza Vaccine market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Recombinant Influenza Vaccine market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Sanofi
Segment by Type
Vial
Prefilled
Segment by Application
Public Sector
Private Sector
Segment by Region
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Recombinant Influenza Vaccine plant distribution, commercial date of Recombinant Influenza Vaccine, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Recombinant Influenza Vaccine introduction, etc. Recombinant Influenza Vaccine Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports’s Conclusions of Recombinant Influenza Vaccine
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices